On March 6, 2020, AnaptysBio, Inc. (“AnaptysBio”) mutually agreed with Marco Londei, the Chief Medical Officer of AnaptysBio, to end his employment effective March 25, 2020. AnaptysBio has initiated recruitment of a new Chief Medical Officer to lead development of AnaptysBio’s clinical product pipeline. In the interim, J. Anthony Ware, MD, who joined the Board of Directors of AnaptysBio in August 2017, and previously served as Senior Vice President of Product Development at Eli Lilly and Company, will be providing additional oversight to AnaptysBio’s clinical and regulatory functions.